Medical devices industry private equity deals in Q3 2020 total $2.81bn globally

3 November 2020 (Last Updated November 3rd, 2020 07:42)

Medical devices industry private equity deals in Q3 2020 total $2.81bn globally

Total medical devices industry private equity deals in Q3 2020 worth $2.81bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked an increase of 67.3% over the previous quarter and a rise of 114.8% when compared with the last four-quarter average, which stood at $1.31bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $1.68bn. At the country level, the US topped the list in terms of deal value at $1.68bn.

In terms of volumes, North America emerged as the top region for medical devices industry private equity deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of private equity deals activity in Q3 2020 was the US with 25 deals, followed by China with four and Israel with three.

In 2020, as of the end of Q3 2020, medical devices private equity deals worth $5.49bn were announced globally, marking an increase of 146.2% year on year.

Medical devices industry private equity deals in Q3 2020: Top deals

The top five medical devices industry private equity deals accounted for 66.7% of the overall value during Q3 2020.

The combined value of the top five medical devices private equity deals stood at $1.87bn, against the overall value of $2.81bn recorded for the month.

The top five medical devices industry deals of Q3 2020 tracked by GlobalData were:

1) ASP Navigate Acquisition’s $825m private equity deal with NN

2) The $350m private equity deal with North American Science Associates by ArchiMed

3) Jiaxing Biolink Hongrun Venture Capital, Tianjin Ronghao Enterprise Management Partnership (LLP), Tianjin Yuanyi Yuanfu Enterprise Management Center (Limited Partnership), Yifang Huida Venture Capital (Guangdong) Partnership (Limited Partnership), Yifang Yida (Guangdong) Investment Partnership (Limited Partnership) and Zhuhai Gaoling Chongheng Equity Investment Enterprise (Limited Partnership)’s $291.1m private equity deal with MicroPort Medbot (Shanghai)

4) The $218.33m private equity deal with MicroPort Medbot (Shanghai) by Jiaxing Biolink Hongrun Venture Capital, Tianjin Ronghao Enterprise Management Partnership (LLP), Tianjin Yuanyi Yuanfu Enterprise Management Center (Limited Partnership), Yifang Huida Venture Capital (Guangdong) Partnership (Limited Partnership), Yifang Yida (Guangdong) Investment Partnership (Limited Partnership) and Zhuhai Gaoling Chongheng Equity Investment Enterprise (Limited Partnership)

5) One Equity Partners’s private equity deal with AdaptHealth for $190m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.